LIPO Lipella Pharmaceuticals Inc.

Subscribe to $LIPO

Lipella Pharmaceuticals Inc.

Subscribe to $LIPO

$LIPO

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2022

Exchange: NASDAQ

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Date	Price Target	Rating	Analyst

See more ratings

Lipella Pharmaceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting
PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today issued a letter from Chief Executive Officer Jonathan Kaufman to stockholders. The letter provides detailed responses to frequently asked questions regarding the Company's recent delisting from the Nasdaq Capital Market, as well as insight into Lipella's clinical programs, financial position, and plans to relist on a national exchange. In the letter, Dr. Kaufman acknowledged the many inquiries received from stockholders and reaffirmed the Company's commitmen
6/25/25 3:15:00 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the Nasdaq Hearings Panel has determined to delist the Company's common stock from The Nasdaq Capital Market. Trading in the common stock was suspended at the open of business today. The delisting follows Nasdaq's determination that certain private placement transactions completed between December 2024 and March 2025 did not comply with Listing Rules 5100 (Public Interest Concern), 5635 (Shareholder Approval), and 5640 (Voting Rights). Spec
6/20/25 3:19:25 PM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology
PITTSBURGH, June 17, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced the issuance of U.S. Patent No. 12,326,492, titled "Systems and Methods of Detecting Interstitial Cystitis." The patent was issued by the United States Patent and Trademark Office on June 10, 2025, and provides protection through at least 2045, subject to potential extensions. The patent covers a method, using magnetic resonance imaging (MRI), to detect lesions (or permeability defects) in body cavities. "This method can potentially provide enha
6/17/25 8:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development
PITTSBURGH, June 04, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet need, today announced that it has re-signed its manufacturing collaboration agreement with Cook MyoSite, Inc. ("Cook MyoSite") to support Chemistry, Manufacturing and Control (CMC) documentation supporting our clinical products LP-10 and LP-310. Dr. Jonathan Kaufman, Chief Executive Officer and Co-Founder of Lipella, said, "We are pleased to renew our collaboration with Cook MyoSite, a trusted partner with a strong track record in high-quality manufacturing. This CMC
6/4/25 8:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting
Statistically significant safety and efficacy data from 0.25 mg and 0.50 mg cohorts to be presented Presentation scheduled for Thursday, May 15, 2025, at 11:36 a.m. PT PITTSBURGH, May 15, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that topline data from the first two dose cohorts of its ongoing Phase 2a trial of LP-310 (liposomal tacrolimus oral rinse) for the treatment of Oral Lichen Planus (OLP) will be presented at the 2025 joint international meeting of the American Academy of Oral Me
5/15/25 9:00:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"
Joint meeting to be held in Las Vegas, May 14-17 Presentation will be delivered by Dr. Alessandro Villa of Miami Cancer Institute Topline study results demonstrate clinically meaningful improvements in OLP Visible lesion resolution during treatment; return toward baseline post-dosing supports localized activity PITTSBURGH, April 23, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "we," "our," or the "Company"), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that its abstract on LP-10 for the treatment of Oral Lichen Planus (OLP) has been accepted for podium presentation at
4/23/25 8:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement PITTSBURGH, April 22, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced positive topline results from the second cohort (0.50 mg) of its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal-tacrolimus oral rinse formulation of
4/22/25 5:30:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the completion of enrollment in its Phase 2a multicenter, dose-ranging trial evaluating LP-310, a liposomal tacrolimus oral rinse for the treatment of oral lichen planus (OLP). The Phase 2a trial has now fully enrolled participants across all three dose cohorts (0.25 mg, 0.50 mg and 1.0 mg of tacrolimus) at seven U.S. study sites. Topline results from the final cohort (1.0 mg) remain on track for the second quarter of 2025 and will represent the most
4/8/25 5:00:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast
PITTSBURGH, March 31, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our," "us," or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announced that Co-Founder and Chief Medical Officer Dr. Michael Chancellor is featured in the latest episode of The Pharmaverse Podcast, hosted by pharmaceutical industry executive recruiter Michael Pietrack. The episode, titled "From Medicine to Biotech Innovation," offers an inside look at Dr. Chancellor's journey from clinical medicine to biotech leadership. In this candid conversation, he discusses how Lipella's innovation was born out of unmet medical
3/31/25 11:00:00 AM ET
$LIPO
Biotechnology: Pharmaceutical Preparations
Health Care
Spartan Capital Securities, LLC Announces Key February Transactions
New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries. Spartan Capital successfully served as the sole placement agent for Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) in a $3.788 million private placement. This financing represents an important milestone in Lipella's efforts to advance its clinical pipeline and address significant unmet medical needs under the leadership of CEO Dr. Jonathan Kaufman. The firm also played a key role as Co-Place
3/7/25 4:56:47 PM ET
$HCTI
$LIPO
EDP Services
Technology
Biotechnology: Pharmaceutical Preparations
Health Care

Lipella Pharmaceuticals Inc.

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc.

Recent Analyst Ratings for Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

Kaufman Jonathan H bought $45,452 worth of shares (55,000 units at $0.83), increasing direct ownership by 7% to 888,849 units (SEC Form 4)

Lipella Pharmaceuticals Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

SEC Form 4 filed by Officer Kaufman Jonathan H

Kaufman Jonathan H bought $7,590 worth of shares (10,000 units at $0.76), increasing direct ownership by 1% to 898,849 units (SEC Form 4)

SEC Form 4 filed by Pruchnic Ryan

SEC Form 4 filed by Yoshimura Naoki

Lipella Pharmaceuticals Inc. SEC Filings

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

SEC Form PRE 14A filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

SEC Form 10-Q filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Other Events

Lipella Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

SEC Form 8-K filed by Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. Press Releases

Fastest customizable press release news feed in the world

Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting

Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market

Lipella Pharmaceuticals Announces U.S. Patent Issuance for Diagnostic Technology

Lipella Pharmaceuticals Re-signs Manufacturing Collaboration Agreement with Cook MyoSite to Support LP-310 Clinical Development

Lipella Pharmaceuticals to Present Phase 2a Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on "Global Transformation in Oral Medicine"

Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025

Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus

Lipella Pharmaceuticals Co-Founder Michael Chancellor Featured on the Pharmaverse Podcast

Spartan Capital Securities, LLC Announces Key February Transactions

Lipella Pharmaceuticals Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

Amendment: SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc.

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)

SEC Form SC 13D/A filed by Lipella Pharmaceuticals Inc. (Amendment)